MedCap AB (DE:61MA)
FRANKFURT:61MA
61MA Stock Chart & Stats
€50.30
€0.90(1.70%)
At close: 4:00 PM EST
€50.30
€0.90(1.70%)
Day’s Range― - ―
52-Week Range€29.40 - €59.60
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€673.82M
Enterprise Value€7.68B
Total Cash (Recent Filing)€370.40M
Total Debt (Recent Filing)€707.00M
Price to Earnings (P/E)37.4
Beta0.14
Next Earnings
Apr 29, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.44
Shares Outstanding15,077,583
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio7.70
Price to Book (P/B)5.67
Price to Sales (P/S)3.90
P/FCF Ratio29.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.04
Revenue Forecast (FY)€210.38M
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue ScalingSustained revenue growth from ~0.8B to ~2.1B over the period indicates durable demand for MedCap’s consolidated subsidiaries and validates its roll-up strategy. This scale improves pricing leverage, supports reinvestment capacity, and lowers per-unit costs, aiding medium-term margin resilience.
Consistent Operating ProfitabilityMid-teens EBIT margins and roughly 10–11% net margins reflect a structurally profitable operating model across portfolio companies. Persistent operating profitability creates internal cash generation for capex, acquisitions and dividends, and provides a buffer against cyclical pressure in healthcare spending.
Acquisition-driven Niche Healthcare ModelA focused buy-and-build model targeting niche medical and diagnostic businesses offers durable competitive benefits: concentration in fragmented subsegments enables pricing power, operational improvements, and bolt-on synergies that can compound returns and stabilize revenue over multiple years.
Bears Say
Rising Leverage In 2025A meaningful step-up in debt and debt-to-equity reduces balance-sheet flexibility and increases interest and refinancing risk. For an operator of portfolio healthcare firms, higher leverage constrains ability to pursue opportunistic add-ons, fund working-capital swings, or absorb operational shocks.
Inconsistent Cash ConversionFree cash flow is positive but conversion is uneven, with operating cash flow below earnings in several years. Persistent working-capital volatility or timing effects can strain liquidity, complicate upstreaming of cash from subsidiaries, and make debt servicing and acquisition funding less predictable.
2025 Gross-margin DeteriorationA sharp gross-margin decline signals potential mix shifts, pricing pressure, or cost inflation in 2025. If structural rather than one-off, it could compress sustainable margins across subsidiaries, reducing free cash flow and limiting the firm’s ability to invest in growth or complete value-creating acquisitions.
MedCap AB News
61MA FAQ
What was MedCap AB’s price range in the past 12 months?
MedCap AB lowest stock price was €29.40 and its highest was €59.60 in the past 12 months.
What is MedCap AB’s market cap?
MedCap AB’s market cap is €673.82M.
When is MedCap AB’s upcoming earnings report date?
MedCap AB’s upcoming earnings report date is Apr 29, 2026 which is in 27 days.
How were MedCap AB’s earnings last quarter?
MedCap AB released its earnings results on Feb 06, 2026. The company reported €0.438 earnings per share for the quarter, beating the consensus estimate of €0.435 by €0.003.
Is MedCap AB overvalued?
According to Wall Street analysts MedCap AB’s price is currently Overvalued.
Does MedCap AB pay dividends?
MedCap AB does not currently pay dividends.
What is MedCap AB’s EPS estimate?
MedCap AB’s EPS estimate is 0.43.
How many shares outstanding does MedCap AB have?
MedCap AB has 15,077,583 shares outstanding.
What happened to MedCap AB’s price movement after its last earnings report?
MedCap AB reported an EPS of €0.438 in its last earnings report, beating expectations of €0.435. Following the earnings report the stock price went up 8.994%.
Which hedge fund is a major shareholder of MedCap AB?
Currently, no hedge funds are holding shares in DE:61MA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedCap AB
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, and pharmaceuticals companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Northern Europe. It typically invests between SEK25 million ($2.75 million) to SEK150 million ($16.51 million) with enterprise value and sales revenue between SEK50 million ($5.90 million) to SEK200 million ($23.06 million) and EBITDA between SEK1 million ($0.11 million) to SEK50 million ($5.50 million). The firm seeks to acquire stakes between 20% and 50% in its portfolio companies. It uses its capital and loans and makes balance sheet investments. MedCap AB (publ) was founded in 2001 and is based in Stockholm, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---